Nabta Health Secures $2 Million in Pre-Series A Funding Round
Nabta Health, the UAE-based pioneer in women’s health technology, has successfully closed a US $2 million Pre-Series A funding round, bringing its total funding to US $4.5 million to date. This milestone reinforces the company’s commitment to reimagining women’s healthcare across the Middle East through an AI-powered hybrid care model that integrates virtual, at-home, and in-clinic services.
Built on culturally compliant design and AI-driven clinical pathways, NABTA enables women to identify, diagnose, and manage chronic health conditions throughout different life stages—addressing a long-standing gap in equitable, outcomes-based care across the region.
In 2025, NABTA was recognized on TIME Magazine’s Top HealthTech Companies list, announced the launch of a Women’s Health Centre of Excellence in partnership with Clemenceau Medical Center Hospital Dubai, and expanded its corporate women’s health solutions across the Middle East.
The newly secured funding will accelerate NABTA’s mission to deliver accessible, evidence-based women’s healthcare and scale its hybrid model across the Middle East and Africa. The investment will support deeper partnerships with employers, insurers, and healthcare providers, the introduction of new diagnostic and at-home testing pathways, and the enhancement of the company’s clinical infrastructure in collaboration with leading hospitals in the region.
Sophie Smith, Founder and CEO of Nabta Health, said:
“We are delighted to have closed this Pre-Series A round and to bring our total funding to date to US$4.5 million. This investment validates our vision – that women’s health in the region can be reimagined through an AI-powered, hybrid care model that meets women where they are, respects cultural context and delivers measurable outcomes.”
She added:
“For employers and insurers in the region, addressing the women’s health gap is not just a moral imperative; it is a business and productivity one.”
Iain McMillan, Chair of Nabta Health, commented:
“The closing of this Pre-Series A round is confirmation that Nabta Health is being increasingly recognised in the region as a key enabler of measurably better women’s health.”
